Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors




Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

Initiation of trial marks milestone for Crinetics’ novel nonpeptide drug conjugate platform

SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic or locally advanced somatostatin receptor type 2 (SST2)-positive neuroendocrine tumors and other SST2-expressing solid tumors. CRN09682 is the lead candidate from Crinetics’ proprietary nonpeptide drug conjugate (NDC) platform, which leverages the company’s expertise in GPCR drug discovery and small molecule design to develop a pipeline of modular targeted therapies for endocrine and endocrine-related tumors.

“We developed CRN09682 to address the need for a more efficacious, safer, and convenient targeted therapy for patients with SST2-expressing tumors,” said Stephen Betz, Ph.D., Chief Scientific Officer and Co-Founder of Crinetics. “Dosing the first patient in the Phase 1/2 study marks a major milestone for CRN09682 and our NDC platform as a whole. CRN09682 is the first clinical exploration of this new modality, which we believe has the potential to unlock a new generation of receptor-targeted therapies to treat tumors with precision.”

CRN09682 was designed to bind selectively and with high potency to SST2-expressing tumor cells, promoting rapid receptor internalization and linker cleavage to release a potent cytotoxic payload directly within the tumor. This targeted approach is intended to concentrate treatment at the tumor site, by optimizing tumor penetration and limiting systemic exposure and related toxicities. NDCs are manufactured by traditional chemical synthesis methods, eliminating manufacturing constraints and specialized handling required by most antibody drug conjugates and radiopharmaceuticals.

The Phase 1/2 BRAVESST₂ trial is a first-in-human, open-label, dose-escalation study with a dose expansion phase designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CRN09682. The Phase 1 portion will enroll patients in escalating dose cohorts to determine the maximum tolerated dose and recommended dose for the expansion phase. Phase 2 will further evaluate and characterize CRN09682 in selected SST2-expressing tumor types. Up to 150 participants are expected to be enrolled across both phases. Eligible patients must have metastatic or locally advanced disease progression following standard therapies and SST2-expressing tumors confirmed by somatostatin receptor imaging.

For more information about the BRAVESST₂ trial, visit https://bit.ly/4hMl8qc

ABOUT CRN09682

CRN09682 is an investigational, first-in-class, non-radioactive, nonpeptide drug conjugate (NDC) linking a somatostatin receptor 2 (SST2) agonist with the cytotoxic drug monomethyl auristatin E (MMAE) via a spacer and a cleavable linker for the treatment of neuroendocrine tumors and other solid tumors that express SST2. The ligand on the CRN09682 binds to SST2 on the tumor cell surface and is internalized into the cell whereby enzymes cleave the MMAE and release it within the cell. MMAE is known to cause microtubule disruption leading to cell arrest and death. The NDC approach is intended to enhance tumor penetration and intracellularly release a potent anti-tumor agent, while minimizing systemic exposure and associated toxicities. Additionally, NDCs are manufactured by traditional chemical synthesis methods, avoiding the limitations of fermentation, bioconjugation, and heterogeneous manufacturing methods required by most antibody drug conjugates. NETs are generally incurable when metastatic, regardless of tumor grade. Overall survival rates vary significantly by stage, grade, age at diagnosis, primary site, and time period of diagnosis.

About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.

Crinetics’ lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics’ deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in late-stage development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. Additional discovery programs address a variety of endocrine conditions such as neuroendocrine tumors, Graves’ disease (including Graves’ hyperthyroidism and Graves’ orbitopathy, or thyroid eye disease), polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the plans and timelines for the clinical development of CRN09682 including studies to evaluate whether it is an efficacious or safe therapy for patients with SST2-expressing tumors; whether the Company’s NDC platform will lead to the precision treatment options or the potential for our development candidates to transition to clinical development; In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “upcoming” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including, without limitation, we may not be able to obtain, maintain and enforce our patents and other intellectual property rights, and it may be prohibitively difficult or costly to protect such rights; geopolitical events may disrupt Crinetics’ business and that of the third parties on which it depends, including delaying or otherwise disrupting its clinical studies and preclinical studies, manufacturing and supply chain, or impairing employee productivity; unexpected adverse side effects, complications and/or drug interactions or inadequate efficacy of the Company’s product candidates that may limit their development, regulatory approval and/or commercialization; the Company’s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the success of Crinetics’ clinical studies and nonclinical studies; regulatory developments or political changes, including policies related to pricing and pharmaceutical drug reimbursement, in the United States and foreign countries; clinical studies and preclinical studies may not proceed at the time or in the manner expected, or at all; the timing and outcome of research, development and regulatory review is uncertain, and Crinetics’ drug candidates may not advance in development or be approved for marketing; Crinetics may use its capital resources sooner than expected or our cash burn rate may accelerate; any future impacts to our business resulting from geopolitical developments outside our control; and the other risks and uncertainties described in the Company’s periodic filings with the Securities and Exchange Commission (SEC). The events and circumstances reflected in the company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading “Risk Factors” in Crinetics’ periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075

Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340

Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors




Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors

– Initial clinical data expected mid-2026 –

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the patients in the first cohort have been dosed in its Phase 1 trial evaluating STRO-004 in a range of Tissue Factor (TF) expressing solid tumors. STRO-004 is the Company’s TF-targeting exatecan ADC engineered for best-in-class stability, potency, and tumor selectivity using Sutro’s proprietary cell-free platform.

“Dosing the initial patients in this trial marks an important milestone in bringing forward new treatment options for patients with TF–expressing cancers—many of whom face limited therapy options and difficult prognoses. We’ve seen strong engagement from our clinical investigators, who recognize the potential of STRO-004 to address a pressing need in oncology—and we’re proud of the speed and precision with which our team brought the program into the clinic,” said Jane Chung, Chief Executive Officer of Sutro Biopharma. “STRO-004 is engineered to deliver potent, sustained anti-tumor activity and higher exposure compared to approved therapies, with the goal of reaching tumors that are resistant to standard approaches. Through this trial, we aim to generate early insights into safety and activity that will guide development in areas of urgent unmet need. We are deeply grateful to the patients and investigators participating in this study and look forward to sharing initial data in mid-2026.”

The Phase 1 open-label, multicenter trial is designed to evaluate the safety, pharmacokinetics, and preliminary anti-tumor activity of STRO-004 in patients with advanced TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, and bladder cancer. The dose-escalation phase includes multiple cohorts with ascending dose levels, supported by strong tolerability in non-human primates at up to 50 mg/kg. Sutro’s design enables high entry doses, with the goal of rapidly identifying a recommended Phase 2 dose and early signs of clinical activity.

More information can be found at: https://clinicaltrials.gov/study/NCT07227168.

About STRO-004
STRO-004 is a next-generation antibody-drug conjugate (ADC) targeting tissue factor (TF), a clinically validated tumor-associated antigen expressed across multiple solid tumors. In preclinical studies, STRO-004 demonstrated robust anti-tumor activity, favorable tolerability, and higher exposure compared to approved therapies. Developed using Sutro Biopharma’s proprietary cell-free platform, STRO-004 features an Fc-silent, high affinity antibody, with site-specific β-glucuronidase cleavable linker and exatecan payload at a drug-to-antibody ratio of 8 (DAR8). This design aims to enhance stability, reduce off-target toxicity, and maximize efficacy. It is currently being evaluated in a Phase 1 trial in patients with a range of TF-expressing solid tumors.

About Sutro Biopharma  
Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.

For more information, follow Sutro on social media @Sutrobio or visit www.sutrobio.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated preclinical and clinical development activities; timing of announcements of clinical results; potential efficacy, safety and benefits of STRO-004; potential insights gained and benefits of the Phase 1 trial design; and potential benefits of the Company’s other product candidates and platform. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the Company’s ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, the market size for the Company’s product candidates to be smaller than anticipated, clinical trial sites, supply chain and manufacturing facilities, the Company’s ability to obtain, maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, the Company’s ability to fund development activities and achieve development goals, the Company’s ability to protect intellectual property, and the Company’s commercial collaborations with third parties and other risks and uncertainties described under the heading “Risk Factors” in documents the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. 

Investor Contact
Emily White
Sutro Biopharma
(650) 823-7681
ewhite@sutrobio.com

Media Contact
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com

March Biosciences Announces Appointment of Gurpreet Ratra, Ph.D., as Chief Business Officer




March Biosciences Announces Appointment of Gurpreet Ratra, Ph.D., as Chief Business Officer

Biotech veteran with over 25 years of business development, strategy and operational experience joins March Bio’s management team

HOUSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) — March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, today announced the appointment of Gurpreet Ratra, Ph.D., as Chief Business Officer.

Dr. Ratra brings over 25 years of experience in the life science industry, including cell and gene therapy leadership and equity research. In this newly created role at March Bio, Dr. Ratra will oversee business development and corporate strategy initiatives.

“We are delighted to welcome Gurpreet to March Bio,” said Sarah Hein, Ph.D., Co-Founder and Chief Executive Officer of March Biosciences. “His proven expertise in shaping strategy and driving successful transactions will be invaluable as we advance our lead program MB-105 through Phase 2 studies for T-cell lymphoma. We recently received RMAT designation from the FDA, creating a path towards MB-105’s potential accelerated approval.”

Dr. Ratra commented, “I look forward to working closely with my colleagues to further develop our corporate strategy. There is much potential in leveraging March Bio’s comprehensive CAR-T cell therapy pipeline to pursue transformative business transactions and collaborations.”

Most recently, Dr. Ratra served as Chief Business Officer at Kate Therapeutics, where he led business development, finance and human resources functions. Prior to that, he was Chief Business Officer at Skyline TX and Head of Business Development at Spark Therapeutics (now part of Roche), where he played an integral role in completing several large pharma licensing agreements and managing collaborations. Earlier in his career, he held leadership positions at Adverum Biotech and Intrexon Corporation, and conducted equity research at the investment bank Piper Jaffray (now Piper Sandler).

Dr. Ratra holds a Ph.D. in Pharmacology and Toxicology from the University of London, St. Bartholomew’s Medical School, and an MBA from the University of California, Berkeley’s Haas School of Business.

About MB-105
MB-105 is a potential first-in-class autologous CD5-targeted CAR-T cell therapy in development for CD5-positive hematologic malignancies, including T-cell lymphoma (TCL), T-cell acute lymphoblastic leukemia (T-ALL), chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL). The therapy employs a proprietary CAR design that enables selective targeting of malignant cells and streamlined manufacturing without additional genetic manipulation. MB-105 has received Orphan Drug Designation and the Regenerative Medicine Advanced Therapy designation from the FDA for the treatment of relapsed/refractory CD5-positive TCL. The multicenter Phase 2 trial (NCT06534060) is enrolling at twelve sites across the United States.

About March Biosciences
Houston-based March Biosciences, launched from the Center for Cell and Gene Therapy (Baylor College of Medicine, Houston Methodist Hospital, Texas Children’s Hospital), is dedicated to addressing challenging cancers unresponsive to current immunotherapies. Its lead asset, MB-105, is a CD5-targeted CAR-T cell therapy currently in Phase 2 clinical development for patients with relapsed/refractory T-cell lymphoma. March Biosciences is backed by leading life-sciences investors including 4BIO Capital, Mission BioCapital, TMC Venture Fund, Volnay Therapeutics, Alexandria Venture Investments, KdT Ventures, Mansueto Investments, Modi Ventures, Portal Innovations, and the Cancer Focus Fund, as well as non-dilutive support from the Cancer Prevention & Research Institute of Texas (CPRIT) and the NIH SBIR program.

Learn more at www.march.bio.

Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Any statement describing March Biosciences’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as “believes,” “expects,” “anticipates,” “could,” “should,” “would,” “seeks,” “aims,” “plans,” “potential,” “will,” “milestone” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those projected in these forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the clinical development of MB-105, the progress of clinical trials for pipeline candidates, regulatory approvals, market demand for new therapies, competitive dynamics in the biotechnology sector, and macroeconomic conditions.

Contacts:

Corporate:
Business Communications
corporate@march.bio

Media:
Josephine Galatioto
ICR Healthcare
MarchBioPR@icrhealthcare.com

Apyx Medical Corporation Announces Approval and Commercial Launch of Apyx One Console and Single-Use Handpieces for Cosmetic Surgical Procedures in South Korea




Apyx Medical Corporation Announces Approval and Commercial Launch of Apyx One Console and Single-Use Handpieces for Cosmetic Surgical Procedures in South Korea

Initial commercial orders for the Apyx One console in South Korea are expected in Q4 2025

CLEARWATER, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) — Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion^® and the AYON Body Contouring System™ (AYON), today announced the approval and commercial launch of the Apyx One console and single-use handpieces in South Korea following the recent regulatory approval by the Ministry of Food and Drug Safety (MFDS). The Company plans to start shipping Apyx One consoles and single-use handpieces to South Korea to fill initial orders starting in the fourth quarter of 2025.

The Apyx One console is a multi-functional generator incorporating an advanced 3-in-1 energy system that enables plastic and cosmetic surgeons to utilize Renuvion technology, together with full monopolar and bipolar energy. Key features of the Apyx One console include adaptive and intuitive touch screens, procedural presets by body part, quantification of energy delivered to a body area, and an advanced gas system that measures and monitors gas volume and usage.

“Seoul is widely regarded as the cosmetic surgery capital of the world, supported by a thriving medical tourism industry. We are excited to launch commercial sales of the Apyx One console in South Korea, where the cosmetic surgery market is estimated to be $1.7 billion in 2024 and projected to exceed $3.9 billion by 2033¹,” said Charlie Goodwin, President and CEO of Apyx Medical Corporation. “Much like in the U.S. and Europe, the GLP-1 weight-loss drug market in South Korea has grown rapidly over the past two years. As a result, we anticipate there to be a growing number of patients seeking solutions for loose and lax skin following significant weight loss. This is an ideal market for our innovative body contouring technology to build on our success across the U.S. and Europe.”

Source:
      1)    IMARC Group, “South Korea Cosmetic Surgery Market Report, 2024–2033”

Investor Relations Contact:

Jeremy Feffer, Managing Director LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com

About Apyx Medical Corporation:

Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion^® and the AYON Body Contouring System™ in the cosmetic surgery market and J-Plasma^® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, tissue contraction, and electrosurgical capabilities, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.

Cautionary Statement on Forward-Looking Statements:

Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to, statements regarding the Company’s anticipated public offering, including the completion of the public offering on the anticipated terms and the use of proceeds therefrom, projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency or instrumentality including but not limited to the U.S. Food and Drug Administration (the “FDA”), supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those matters on the Company’s financial performance.

Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause the Company’s actual results to differ materially and that could impact the Company and the statements contained in this release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company is subject to, including the Company’s ability to gain requisite approvals for its products from the FDA and other governmental and regulatory bodies, both domestically and internationally; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations; and other risks that are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and the Company’s other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

Curium Establishes Legal Entity in China




Curium Establishes Legal Entity in China

• Curium has established a legal entity in China which represents a major milestone in Curium’s international growth strategy and will enhance Curium’s ability to serve patients with cancer across Asia
• Curium’s local footprint will strengthen collaboration with key partners and align with their long-term vision to build a next-generation pipeline of radiopharmaceuticals for therapy

BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) — Curium has established a legal entity in China, Curium Shanghai Pharmaceuticals Co., Ltd. (科锐霖（上海）医药有限公司), representing a major milestone in Curium’s growth strategy and goal to help diagnose and treat more patients with cancer worldwide.

This important step reinforces the strategic importance of the Chinese market and Curium’s long-term commitment to supporting its healthcare ecosystem. Curium’s local footprint in China will enhance Curium group’s ability to serve patients with cancer and improve access to life-enhancing diagnostic and therapeutic radiopharmaceuticals.

The creation of Curium Shanghai Pharmaceuticals Co., Ltd. will strengthen collaboration with key partners in China and encourage science-led discussions that align with Curium group’s long-term vision to actively build a next-generation pipeline of radiopharmaceuticals for therapy, with global ambition and the scale to pursue high-value opportunities across targets, modalities, and isotopes.

Licardo Chan, General Manager NASIA, Curium International, says, “Curium’s new entity in China will enable continued investment in innovation, operations and talent, supporting sustainable long-term growth for Curium and improving access to essential diagnostic and therapeutic radiopharmaceuticals for patients with cancer.”

About Curium

Curium Pharma is a leading global radiopharmaceutical company with proven expertise in the development, manufacturing and supply of radiopharmaceuticals that transform the way cancer is diagnosed and treated. Headquartered in Boston with offices around the world, Curium’s mission is to find new and better ways to diagnose and treat cancer.

With a global footprint that extends to more than 70 countries, a skilled and dedicated team of over 5,000 employees, and four manufacturing sites, Curium is uniquely qualified to meet the significant supply and distribution of established products that underlie success in the radiopharmaceuticals market. Curium’s global leadership is embodied in a diverse and extensive portfolio of over 45 products, that advance patient care for a wide range of cancers.

Curium’s pioneering legacy in nuclear medicine is the foundation of the company’s dedication to innovation and portfolio expansion to cancer therapeutics, particularly in neuroendocrine tumors and with a late-stage pipeline exploring opportunities in prostate cancer.

To learn more, visit www.curiumpharma.com.

Inquiries:

Curium Group

Camilla Campell

VP, Head of Global Communications

Camilla.campbell@curiumpharma.com

Actithera appoints radiopharmaceutical pioneer Dr. Darshan Dalal as Chief Medical Officer




Actithera appoints radiopharmaceutical pioneer Dr. Darshan Dalal as Chief Medical Officer

• Internationally recognized radiopharmaceutical leader joins Actithera as the lead FAP-targeting asset advances to clinical development and the differentiated pipeline takes shape
• Brings over 15 years of global oncology and hematology leadership, advancing over 10 radioligands across the development spectrum, from preclinical to Phase III

OSLO, Norway and CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) — Actithera (“the Company”), a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapies (RLTs), today announced the appointment of Darshan Dalal, M.D., PhD, MPH as Chief Medical Officer (CMO). In this role, Dr. Dalal will lead the clinical strategy and build the clinical development organization as Actithera advances its lead fibroblast activation protein (FAP)-targeting RLT into the clinic and builds its pipeline of differentiated precision-engineered radiopharmaceuticals.

Dr. Dalal is a highly experienced radiopharmaceutical leader, bringing over 15 years of global leadership in oncology and hematology. He has a proven track record of advancing more than 10 radioligands in various stages of development ranging from preclinical through to Phase III.

Dr. Dalal has held leadership roles at AstraZeneca and Novartis, where he led global teams with full end-to-end development accountability of multiple radioligands including a key role in the development of Pluvicto, one of the field’s most successful RLTs. He has also been instrumental in more than $8 billion in M&A activity within the RLT space over the last seven years.

Dr. Andreas Goutopoulos, Chief Executive Officer of Actithera, commented: “Darshan’s appointment marks an important milestone for Actithera. His track record in progressing radioligand assets from concept to late-stage development aligns perfectly with our ambition to rapidly advance our FAP-targeting and other pipeline assets into the clinic. Darshan’s expertise will strengthen our execution as we build on the momentum of our Series A and enter our next phase of growth.”

Dr. Darshan Dalal, newly appointed Chief Medical Officer of Actithera, added: “Actithera has built a truly differentiated platform grounded in rigorous medicinal chemistry, giving rise to radioligand therapies with the potential for superior binding, tumor retention, selectivity and therapeutic index. I am excited to join the company at this critical inflection point and to work alongside this talented team as we shape a robust clinical development strategy and advance a pipeline of assets designed to transform clinical outcomes and improve lives.”

Actithera’s discovery platform integrates rational drug design and radiochemistry to develop novel small molecule radioligands that address key limitations in radiopharmaceuticals. The Company is progressing a FAP-directed RLT development candidate with best-in-class potential due to its optimal pharmacokinetic profile and tumor specificity.

For further information:
Optimum Strategic Communications
Mary Clark, Isabelle Abdou, Katie Flint
Tel: +44 20 3922 1906
Email: actithera@optimumcomms.com

About Actithera
Headquartered in Oslo, Norway, and Cambridge, Massachusetts, Actithera is a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapies (RLTs). Founded in 2021 by drug discovery innovator Dr. Andreas Goutopoulos, Actithera applies various molecular design strategies, including covalent-targeting and an isotope-agnostic philosophy to invent RLTs with significant differentiation and larger therapeutic windows. In July 2025, the Company raised a $75.5 million Series A financing backed by blue chip investors, to advance its pipeline and accelerate clinical development of its lead FAP-targeting radioligand therapy, with a focus on addressing critical unmet needs in oncology. Learn more at www.actithera.com and on LinkedIn.

Onco3R Therapeutics Announces Completion of First Multiple Ascending Dose Cohort in Phase 1 Trial of Novel SIK3 inhibitor O3R-5671




Onco3R Therapeutics Announces Completion of First Multiple Ascending Dose Cohort in Phase 1 Trial of Novel SIK3 inhibitor O3R-5671

Dosing of first MAD cohort in Phase 1 trial of O3R-5671 complete with no drug related adverse events

Pharmacokinetic profile demonstrates long half-life and low intersubject variability

Pharmacodynamic data from single ascending dose cohorts indicative of profound and sustained TNFα inhibition at low doses

Leuven, Belgium. December 3, 2025. Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming patients’ lives with best-in-class medicines, today announced the successful completion of the first multiple ascending dose (MAD) cohort of subjects in the Phase 1 trial of its novel SIK3 inhibitor O3R-5671. Four single ascending dose (SAD) cohorts have also been completed.

In each of the SAD cohorts, six subjects received a single oral dose of O3R-5671 between 5mg – 35mg. In the first MAD cohort, six subjects received 5mg O3R-5671 once a day for 14 days. Pharmacokinetic and safety data support investigating a higher dose in the second MAD cohort of the study, which is planned to initiate in early December.

Pharmacokinetic data generated to date demonstrate that O3R-5671 has a flat PK profile, a highly attractive attribute of this drug candidate, with a long half-life. Drug exposure in the SAD cohorts is dose proportional with low variability between subjects. A food effect cohort demonstrated that O3R-5671’s PK profile is consistent with or without food indicating that there will be no food restrictions in future patient clinical studies. Data from the first MAD cohort demonstrate that O3R-5671’s attractive PK profile is maintained at day 14 with drug exposure approximately two times higher than the same single 5mg dose.

The safety profile of O3R-5671 is highly encouraging with a low rate of drug related adverse events reported to date. Importantly, no drug related adverse events have been reported in the 25 and 35mg SAD cohorts or in the 5mg MAD cohort and there have been no clinically significant abnormalities on ECG, vital signs or physical examination.

Pharmacodynamic data from the SAD cohorts demonstrate that O3R-5671 potently inhibits TNFα in a dose dependent manner and that maximal inhibition (approximately 90%) is achieved between 25mg and 35mg, the highest dose that has been examined to date. Furthermore, drug levels 24 hours after dosing at 25 and 35mg doses maintained inhibition of TNFα by more than 75%.

“We are very encouraged by the PK, safety and PD data that have been generated to date in the first in human study of O3R-5671” said Pierre Raboisson, PhD, CEO and Founder of Onco3R Therapeutics. “These data exceed the expectations we had for O3R-5671 before we entered the clinic, and we are excited about the prospect of completing this important study and embarking on patient studies in 2026. In addition to potently inhibiting TNFα, our non-clinical data also demonstrate that O3R-5671 potently inhibits IL-23 and IL-12 which, along with TNFα, are implicated in the pathogenesis of a variety of autoimmune diseases including ulcerative colitis, Crohn’s disease and psoriasis.”

He added, “We are highly motivated to discover and develop drugs that will make significant improvements to the lives of patients living with autoimmune diseases and cancer. Specifically for patients with autoimmune diseases, O3R-5671 has the potential to become a safe, effective and convenient therapeutic option and we are looking forward to its continued development.”

About O3R-5671
O3R-5671 has been designed based on more than 12 years of preclinical and clinical data on SIK inhibitors for autoimmune diseases. O3R-5671 is a highly selective SIK3 inhibitor, which has been designed to avoid the toxicities associated with inhibiting SIK1 and SIK2. Furthermore, O3R-5671 does not inhibit other kinases and has demonstrated a highly attractive profile in an extensive safety panel. Preclinical data demonstrated that O3R-5671 inhibits the release of the pro-inflammatory cytokines TNFα and IL-23 and promotes the release of the immunomodulatory cytokine IL-10. These data, along with data from animal models of autoimmune diseases, indicate that O3R-5671 has the potential to treat a variety of autoimmune diseases including ulcerative colitis, Crohn’s Disease, psoriasis, psoriatic arthritis and rheumatoid arthritis.

About the Phase 1 trial of O3R-5671
The first-in-human study is evaluating O3R-5671 in healthy volunteers using a single ascending dose (SAD) and multiple ascending dose (MAD) design. In addition to assessing safety and pharmacokinetics, the trial includes extensive biomarker tests that will provide insights into how O3R-5671 modulates immune responses. The results from the trial will inform the design of subsequent patient trials across a range of autoimmune diseases, which are planned to commence in 2026.

About Onco3R Therapeutics
At Onco3R Therapeutics, we are driven by our purpose to transform the lives of patients with autoimmune diseases and cancer through precision-designed, best-in-class therapies. With over 150 years of combined R&D experience, our team brings deep expertise in disease biology, drug discovery & development, and translational science. We focus on clinically validated targets and select the right therapeutic modality, small or large molecules, to address the underlying disease biology with best-in-class therapies. Our mission is to develop safer, more effective medicines in oncology and immunology that truly make a difference for patients. By integrating learnings from past clinical challenges and applying cutting-edge technologies, we aim to de-risk clinical development and accelerate the delivery of innovative treatments with real-world impact. The company is based in the biotech cluster in Leuven, Belgium. For more information, visit www.onco3r.com or follow us on LinkedIn.

Attachment

• PR- O3R-5671 First MAD cohort completed_final

Elevation Spine Center Expands Bend Clinic to Offer Easier Access to Advanced, Lasting Pain Relief




Elevation Spine Center Expands Bend Clinic to Offer Easier Access to Advanced, Lasting Pain Relief

Bend, OR, Dec. 03, 2025 (GLOBE NEWSWIRE) — Elevation Spine Center, one of the fastest-growing health clinics in Central Oregon, has completed a major expansion of its Bend facility. This expansion, finished on November 1, 2025, means more patients can now access the clinic’s specialized, proven methods for back, neck, sciatica, and disc pain. These methods include Chiropractic BioPhysics® (CBP) corrective care and Advanced DOC Spinal Decompression.

The clinic is known for getting measurable, long-term results and for providing an exceptional patient experience—treating everyone like family, not just a number. This expansion helps the center meet the high demand for solutions that actually fix the root cause of pain, rather than just offering temporary relief.

“We saw that people in Central Oregon needed a better kind of chiropractic care—one based on science that truly fixes the root problem causing their pain,” said Dr. Derek Murray, Owner and Founder of Elevation Spine Center. “Our bigger facility lets us use more advanced equipment and see more patients. We combine the proven structure correction of CBP with the deep healing of DOC decompression. This ensures our patients don’t just feel better for a week, but they can move, feel, and live better for the rest of their lives.”

Finding the Real Problem: Why the Facility Focuses on Correction, Not Quick Fixes

Millions of people worldwide suffer from serious back pain, but often their treatment only covers up the symptoms. Elevation Spine Center uses a different approach. They specialize in Chiropractic BioPhysics® (CBP), which is the most thoroughly researched and effective corrective technique available.

• Science-Backed Correction: CBP® is supported by over 140 studies showing it leads to lasting improvements in how the spine lines up and looks. Unlike basic chiropractic care, CBP uses digital X-rays and detailed analysis to see exactly how a patient’s spine compares to a healthy model. This lets the doctors create a treatment plan specifically for that person.
• The CBP® Method: This specific approach uses a mix of targeted adjustments, special exercises, and sustained spinal stretching (traction). Think of the traction like Invisalign for the spine—it slowly and safely changes the structure to create lasting correction. This focus on fixing the structure is how they achieve relief for long-lasting issues like neck pain, headaches, and sciatica.

Using Advanced DOC Decompression to Heal Damaged Discs

For patients dealing with chronic nerve pain, sciatica, or severe pain from a slipped or herniated disc, Elevation Spine Center uses Advanced DOC Spinal Decompression therapy.

This state-of-the-art machine gently and precisely stretches the spine to take pressure off the damaged discs. Studies show that this non-surgical treatment can:

• Shrink disc bulges by over 25% in as little as three months.
• Result in significant improvements in pain and mobility for 71%–89% of patients.
• Consistently bring real relief from severe back and leg pain.

By using this advanced tool along with CBP, the clinic provides a powerful option for Central Oregon residents who want to avoid surgery and long-term reliance on medication.

A Better Experience: Treating Every Patient Like Family

The commitment to excellent care at Elevation Spine Center starts with the husband-and-wife founders, Dr. Derek and Dr. Alysha Murray. They have created a welcoming, family-centered environment.

Dr. Alysha Murray, Co-Founder, whose own migraines were fixed through structural correction, says their focus is always on the patient: “We believe in preventing problems before they start. Our goal is to help people and families take charge of their health. We take the time to listen, teach, and create a custom plan. When you walk through our doors, you are not just a patient; you are family.”

The clinic also offers specialized services like gentle Pediatric Chiropractic care, Scoliosis Treatment, and full rehabilitation for Auto Accident & Whiplash injuries.

By combining the precision of Chiropractic BioPhysics® and the deep healing of DOC decompression, Elevation Spine Center is providing lasting health solutions and achieving truly life-changing results for the Bend community.

To find out more about how Elevation Spine Center can help achieve long-term spinal health, or to book an appointment, visit its website at elevationspinecenter.com.

About Elevation Spine Center

Elevation Spine Center is a specialized chiropractic clinic in Bend, Oregon, focused on getting long-term results for back pain, neck pain, and sciatica. Led by Dr. Derek and Dr. Alysha Murray, the center uses advanced, science-based methods like Chiropractic BioPhysics® (CBP) and DOC Spinal Decompression. Unlike traditional clinics that offer quick fixes, the team at Elevation Spine Center focuses on correcting the root cause of the problem by fixing the structure of the spine. The facility offers compassionate, family-centered care to help the community live healthier, pain-free lives.

Media Contact
Company Name: Elevation Spine Center
Contact Person: Derek Murray
Email: info@elevationspinecenter.com
Phone: 541-480-0518
Country: United States
Website: https://elevationspinecenter.com

CONTACT: Media Contact
Company Name: Elevation Spine Center
Contact Person: Derek Murray
Email: info@elevationspinecenter.com
Phone: 541-480-0518
Country: United States
Website: https://elevationspinecenter.com

Disposal of 9 real estate assets in Belgium




Disposal of 9 real estate assets in Belgium

Paris, December 3^rd, 2025 – Clariane (CLARI.PA – ISIN FR0010386334) today announces that it has completed the sale of a real estate portfolio in Belgium to Care Property Invest.

This portfolio comprises the buildings of 9 nursing and care homes developed between 2010 and 2025 and operated by Korian Belgium. These homes are located respectively in Soignies (Wallonia), Heers, Lummen, Meldert, Diepenbeek, Heverlee, Halen, Lille and Hoeselt (Flanders).

The facilities will continue to be operated by Korian Belgium under lease agreements concluded for a period of twenty years.

The value of the assets sold amounts to nearly €143 million. Taking into account Clariane’s percentage ownership in this real estate portfolio (52.2%), Clariane’s share amounts to approximately €74 million.

This disposal is part of the Group’s strategy of actively managing its real estate portfolio aimed at continuing to reduce its debt and financial leverage, as a continuation to the asset disposal program completed last July.

About Clariane

Clariane is the leading European community for care in times of vulnerability. It has operations in six countries: Belgium, France, Germany, Italy, the Netherlands and Spain.

The Group relies on the diverse expertise of its 65,000 staff members, who each year provide services to nearly 900,000 patients and residents in three main areas of activity: long-term care homes (Korian, Seniors Residencias etc.), healthcare facilities and services (Inicea, Ita, Grupo 5 etc.), and alternative living solutions (Ages&Vie etc.).

In June 2023, Clariane became a purpose-driven company and added a new corporate purpose, common to all its activities, to its articles of association: “To take care of each person’s humanity in times of vulnerability”.

Clariane has been listed on Euronext Paris, Section B since November 2006. The Group joined the SBF 120 index and the CAC® SBT 1.5° index on 23 September 2024.

Euronext ticker: CLARI.PA – ISIN: FR0010386334

Stéphane Bisseuil                                                        Benoît Lesieur
                        Head of Investor Relations                         Deputy Head of Investor Relations – ESG
        +33 (0)6 58 60 68 69                                                        +33 (0)6 64 80 15 90
                stephane.bisseuil@clariane.com                                benoit.lesieur@clariane.com

        Julie Mary                                                                Florian Bachelet
Press Officer                                                        Press Officer
        +33 (0)6 59 72 50 69                                                                +33 (0)6 79 86 78 23
                julie.mary@clariane.com                                florian.bachelet@clariane.com

Attachment

• PR_Clariane_Disposal of real estate assets in Belgium_FV

Kestra Medical Technologies, Ltd. Announces Pricing of Upsized Primary Public Offering of Common Shares




Kestra Medical Technologies, Ltd. Announces Pricing of Upsized Primary Public Offering of Common Shares

KIRKLAND, Wash., Dec. 02, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced the pricing of its upsized underwritten public offering of 6,000,000 common shares at a price to the public of $23.00 per share. The gross proceeds to Kestra from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $138,000,000. In addition, Kestra has granted the underwriters a 30-day option to purchase up to an additional 900,000 common shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on December 4, 2025, subject to the satisfaction of customary closing conditions.

BofA Securities, Piper Sandler, J.P. Morgan, Goldman Sachs & Co. LLC and Wells Fargo Securities are acting as bookrunners for the offering.

The offering is being made only by means of a prospectus. A preliminary prospectus related to the offering has been filed with the SEC and is available on the SEC’s website located at www.sec.gov. A final prospectus related to the offering will be filed with the SEC. Copies of the preliminary prospectus and, when available, the final prospectus, may be obtained from BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, or by email at dg.prospectus_requests@bofa.com; Piper Sandler, 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, Attention: Prospectus Department, by telephone at 800-747-3924 or by email at prospectus@psc.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; or Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at prospectus-ny@ny.email.gs.com.

A registration statement relating to these securities was filed with the U.S. Securities and Exchange Commission (“SEC”) and was declared effective on December 2, 2025. Copies of the registration statement can be accessed by visiting the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Cautionary Statements Regarding Forward-Looking Information

Except where otherwise noted, the information contained in this press release is as of December 2, 2025. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about, among other topics, Kestra’s expectations regarding the closing of the offering and the grant of the option to purchase additional shares to the underwriters. Statements in this press release that express a belief, expectation or intention, as well as those that are not based on historical fact, as forward-looking statements. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions, and we cannot ensure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning. Among the factors that could cause actual results to differ materially from those currently anticipated include risks and uncertainties related to market conditions, satisfaction of customary closing conditions related to the offering and other risks and uncertainties described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended April 30, 2025 filed with the SEC on July 17, 2025, and in other periodic reports filed by the Company with the SEC. These filings, when made, are available on the Investor Relations section of our website and on the SEC’s website at https://sec.gov/. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

About Kestra
Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected.

CONTACT: Investor contact
Neil Bhalodkar 
neil.bhalodkar@kestramedical.com